Sales & Earnings

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.

Teva has spoken of its US biosimilars alliance with Alvotech, in the wake of several major setbacks for the companies’ plans to launch a biosimilar to AbbVie’s Humira (adalimumab) juggernaut on 1 July.

Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.

Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.

Lupin has pushed the US launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables.

After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.

As Teva prepares to unveil a fresh strategy under new CEO Richard Francis on 18 May, the company has delivered Q1 results along with an update on planned US launches for long-acting injectable risperidone as well as biosimilar adalimumab.

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.